Importantly, blockade of IFNγ through anti-IFNγ antibody (Ab) treatment, abolished the anti-tumor therapeutic effect of SRC-3 KO Tregs, which further solidifies the centrality of the IFNγ/CXCL9 axis to SRC-3 KO Treg-mediated tumor clearance. The gene discussed is CXCL9; the disease is neoplasm.